Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US ...Middle East

PR Newswire - News
Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US
SHANGHAI, March 19, 2023 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus (SLE)...

Hence then, the article about kangpu completes patient enrollment for phase iia clinical trial of kpg 818 in sle in the us was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News